Recent 8-K filings for MRVI

• May 07, 2026 23:59 UTC earnings materiality 0.70 positive item 2.02item 9.01

  Maravai LifeSciences Q1 revenue up 41% to $65.8M; raises full-year guidance

  Q1 2026 revenue $65.8M, up 40.5% YoY; net loss improved to $(6.4)M from $(52.9)M.

• Feb 25, 2026 23:59 UTC earnings materiality 0.65 positive item 2.02item 9.01

  Maravai Q4 revenue $49.9M, net loss $63M; guides 2026 revenue $200-210M

  Q4 revenue $49.9M, net loss $(63.0)M, positive Adj EBITDA $0.5M (non-GAAP).

• Nov 06, 2025 23:59 UTC earnings materiality 0.75 negative item 2.02item 9.01

  Maravai Q3 revenue $41.6M, net loss $45.1M, Adj EBITDA -$10.8M

  Revenue of $41.6 million, net loss of $45.1 million, and Adjusted EBITDA loss of $10.8 million for Q3 2025.

• Aug 11, 2025 23:59 UTC earnings materiality 0.90 negative item 2.02item 2.05item 5.02item 9.01

  Maravai Q2 revenue down 32% to $47.4M; net loss $69.8M; restructuring cuts 25% of workforce

  Q2 revenue $47.4M (-32% YoY); net loss $69.8M (incl. $30.4M goodwill impairment); adjusted EBITDA -$10.4M vs +$13.0M.

• Jul 18, 2025 23:59 UTC other_material materiality 0.65 negative item 4.01item 9.01

  Maravai LifeSciences dismisses EY, appoints Deloitte; material weakness disclosed

  EY dismissed as auditor; Deloitte appointed effective July 16, 2025 for FY 2025.

• Jun 09, 2025 23:59 UTC leadership materiality 0.65 neutral item 5.02item 7.01item 9.01

  Maravai LifeSciences appoints Bernd Brust as CEO, succeeding William Martin

  Bernd Brust named CEO and board member effective June 8, 2025; William Martin resigned as CEO and from board.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event earnings

2 positive 3 negative 4 neutral

source · MRVI on sec.gov